The present disclosure is directed to a molecular signature useful in the identification multiple myeloma cells. The molecular signature advantageously identifies multiple myeloma cells under both normoxic and hypoxic conditions. The disclosed molecular signature may be used to diagnose, prognose and ...
Provided herein are the biomarkers for predicting or monitoring the efficacy of a treatment for multiple myeloma. The use of certain M-protein or other protein levels as biomarkers to predict whether a multiple myeloma treatment is likely to be successful is also provided. Further, the analysis ...
In addition, the combination of miR-1246 and miR-1308 can distinguish MGUS from myeloma patients. CONCLUSION: We have developed a biomarker signature using microRNAs extracted from serum, which has potential as a diagnostic and prognostic tool for multiple myeloma. British Journal of Cancer (2012)...
Proteomic prediction models developed using a large-scale dataset from the UK Biobank Pharma Proteomics Project were superior to clinical models for assessing the 10-year risk of 67 diseases across different types of pathology, including multiple myeloma, motor neuron disease, pulmonary fibrosis, celiac...
Dysregulated long non-coding RNAs (lncRNAs) have been found to have oncogenic and/or tumor suppressive roles in the development and progression of cancer, implying their potentials as novel independent biomarkers for cancer diagnosis and prognosis. However, the prognostic significance of expression profil...
Identification and evaluation of a panel of serum biomarkers for predicting response to thalidomide in multiple myeloma patientsdoi:10.1586/epr.11.42Evaluation of: Rajpal R, Dowling P, Meiller J et al. A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly...
The researchers were also able to show that the normal immune system learns from the CAR T cells how to destroy myeloma cells, which are responsible for malignant growths in the bone marrow. In theclinical study, blood andbone marrowsamples from patients with multiple myeloma were taken before...
Specialty pharmacy for hematologic malignancies. The oral oncology medications used in the treatment of chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and non-Hodgkin's lymphoma... Susan,Fajardo,Felicia,... - 《American Journal of Health System Pharmacy Ajhp Official Journal ...
B cell maturation antigen (BCMA) -targeted multiple myeloma therapy BCMA is expressed in normal B cells, MM cells and malignant B cells [60,61,62]. Several CAR-T cell products targeting BCMA are in advanced clinical development for multiple myeloma (MM), including bb2121, LCAR-B38M, JCA...
Immunodeficiency and immunotherapy in multiple myeloma Multiple myeloma is a malignant tumour of plasma cells that remains incurable for the vast majority of patients, with a median survival of 2鈥 3 years. It i... G Pratt,O Goodyear,P Moss - 《British Journal of Haematology》 被引量: 370...